Trial Profile
A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Ipatasertib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms ECLIPSE
- 29 Sep 2023 This study has been discontinued in Germany, according to European Clinical Trials Database.
- 10 Aug 2022 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
- 10 Aug 2022 Planned primary completion date changed from 30 Jul 2020 to 30 Dec 2022.